RecruitingPhase 2NCT06919081

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Phase II Study of the Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Sponsor

University of Illinois at Chicago

Enrollment

24 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Persistent Corneal Epithelial Defect Corneal Epithelial Disorders

Summary

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome and Vehicle Control for people with corneal epithelial disorders and persistent corneal epithelial defect. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.